Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Post archive for ‘Smith On Stocks Blog’

Part 7: Illegal Naked Shorting: DTCC Continuous Net Settlement and Stock Borrowing Programs Have Loopholes That Facilitate Illegal Naked Shorting

Acronyms Used Frequently in This Report DTCC: The Depository Trust & Clearing Corporation (DTCC) provides clearing and settlement services to the US financial markets that handle the exchange of nearly all securities and cash on behalf of buyers and sellers. It is also a central securities depository providing central custody of almost all US securities. […]

Part 6 Illegal Naked Shorting: The SEC’s Regulation SHO is Intended to Prevent Illegal Naked Shorting, But is Ineffective

Overview In previous blogs I traced the history of stock trading from the 1960s when stock certificates and cash were physically exchanged to settle trades to the paper free, totally electronic system that exists today. Instead of owning stock certificates, we now own digital entries located somewhere in the vaults of the inscrutable Depository Trust […]

Part 5 in Series on Illegal Naked Shorting’s Role in Stock Manipulation: Traditional Shorting Compared to Naked Shorting (Both Legal and Illegal)

Introduction  This is the fifth blog in the series that I am writing to describe how illegal naked shorting is used broadly and massively to manipulate the stock prices of (primarily small) companies. I have been studying illegal naked shorting for nearly five years and I have found it to be incredibly complex and disturbingly […]

Ondexxya Receives Conditional EU Approval as Expected (PTLA, Buy, $36.44)

Portola Pharmaceuticals announced last Friday that the European Commission granted conditional Marketing Authorization for Ondexxya (andexanet alfa). In the US, the product is called Andexxa; it was approved in May 2018. In March, 2019 management said that it expected this EU approval in May. As in the US, the approval was conditional and was based […]

Part 4 in Series on Illegal Naked Shorting’s Role in Stock Manipulation: Who are the Key Players?

Introduction I worked on Wall Street as an analyst for nearly 40 years and was involved in the stock market on a day to day basis. Throughout this time, I was focused on fundamental developments that would give an insight into the potential for a company to grow its sales and profits and then trying […]

Part 3 in Series on Illegal Naked Shorting’s Role in Stock Manipulation – Prime Brokers and the DTCC Have a Troubling Monopoly on Clearing and Settling Stock Trades

Clearing and Settling of Stock Trades Most of us when we enter a buy or sell order for a stock give almost no thought to how key aspects of the trade are carried out. We have great confidence that the trade will be handled in accordance with our instructions and accurately reflected in our brokerage […]

Part 2 in Series on Illegal Naked Shorting’s Role in Stock Manipulation- Conventional Wisdom on How Short Sales are Executed

Introduction The current conventional wisdom on how a short sale is transacted is that a short seller borrows stock from a specific investor who is long the stock, then at some later point buys back the stock in the open market. They then return the stock to that “same specific investor” from whom it was […]

Part 1 in a Series of Reports on Blatant, Widespread Stock Manipulation that is Enabled by Illegal, Naked Shorting

Is There a Way for Companies to Fight Back? Yes!!!!!! I am convinced that price manipulation by Wall Street bad actors is endemic in the capital markets and swindles legitimate investors out of billions of dollars each year. This criminal enterprise is particularly directed against the stocks of emerging growth companies that are at the […]

Today’s Price Action in Cytokinetics (CYTK) and Cryoport (CYRX)

There has been strong price action today in both Cryoport and Cytokinetics so I thought I would make a brief comment on each. At the time of this writing, the intraday price of CYTK is up $1.34 to $9.86 and since March 7, 2019 it is up 64% from $6.02. On March 7, 2019 CYTK […]

Comment on the Sharp Correction in Small Biopharma Stocks

Let me say a word about the stock market and the small biopharma stocks that I am recommending. The second half of 2018 and December in particular have been terrible for the market as a whole and horrendous for small biophama stocks. Many of my recommendations are down sharply from recent prices and sometimes from […]